Status:
NOT_YET_RECRUITING
Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Lead Sponsor:
Farshad Moradi
Conditions:
Refractory Dermatomyostitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory D...
Eligibility Criteria
Inclusion
- Patients with suspected dermatomyositis.
- Patient must be \> 18 years old.
- Be willing and able to provide written informed consent for the trial.
Exclusion
- Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women.
- Contraindication to MRI or inability to lie flat for 30 min
- Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study
Key Trial Info
Start Date :
December 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06568783
Start Date
December 1 2024
End Date
October 1 2028
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94304